🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Atopic Dermatitis (AD)

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry NCT06238765n/a1 site📍 Waltham CorEvitas Reflectance Confocal Microscopy Evaluation of Skin Structure of Patients With Atopic Dermatitis Under Nemolizumab NCT07730788n/a1 site📍 Romans-sur-Isère Hôpitaux Drôme Nord Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization of Mild Atopic Dermatitis Skin Lesions in Pediatric Population NCT07259343NA1 site📍 Aguascalientes Universidad Autónoma de Aguascalientes · Tests: glycomacropeptide, emollient cream SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) NCT07021495n/a8 sites📍 Nijmegen📍 Maastricht📍 Amsterdam Leiden University Medical Center Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease NCT07455578Phase 12 sites📍 Charlestown📍 Birtinya Seismic Therapeutic AU Pty Ltd · Tests: S-4321 A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis NCT07235384Phase 112 sites📍 Woolloongabba📍 Carlton📍 Beijing Zai Lab (Shanghai) Co., Ltd. · Tests: ZL-1503, Placebo, ZL-1503, Placebo Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. NCT06855745Phase 212 sites📍 Brookvale📍 Darlinghurst📍 Kogarah Alphyn Biologics · Tests: zabalafin Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis NCT07895615Phase 21 site📍 Hangzhou Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Tests: LT-002-158, Placebo A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) NCT07355075Phase 2, Phase 31 site📍 Irving Turn Therapeutics · Tests: GX-03, Vehicle Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism NCT04455906n/a1 site📍 Boston Boston Children's Hospital A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis. NCT07230483Phase 21 site📍 Beijing Keymed Biosciences Co.Ltd · Tests: CM512 Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis NCT07746427NA2 sites📍 New York📍 New York Weill Medical College of Cornell University · Tests: Digital App Mindfulness Meditation, Mindfulness Meditation Sheet A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis NCT07558668Phase 114 sites📍 Arkansas City📍 Fremont📍 Plainfield Sitryx Therapeutics Ltd · Tests: SYX-5219 Oral Capsule A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis NCT07604324Phase 11 site📍 Fukuoka Novartis Pharmaceuticals · Tests: DCY636, Placebo Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis NCT07298395Phase 232 sites📍 Birmingham📍 Hot Springs📍 Beverly Hills Enveda Therapeutics · Tests: ENV-294, Placebo A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab NCT06524635Phase 22 sites📍 Sacramento📍 Ann Arbor AbbVie · Tests: Lutikizumab A Phase III Study of GS101 Injection to Dupixent® NCT07386743Phase 31 site📍 Shenyang Jiangsu Genscend Biopharmaceutical Co., Ltd · Tests: GS101 injection, DUPIXENT® Skin Microbial Ecology in Atopic Dermatitis NCT04170244n/a1 site📍 Rochester University of Rochester · Tests: AD subject visit sampling procedures, PS subject visit sampling procedures, Healthy control visit sampling procedures A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) NCT07239947Phase 110 sites📍 Hefei📍 Wuhu📍 Beijing Bambusa Therapeutics · Tests: BBT001, Placebo Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD NCT07441395Phase 21 site📍 South San Francisco Corvus Pharmaceuticals, Inc. · Tests: Soquelitinib, Placebo Effect of Partially Hydrolyzed Formula With Synbiotics on Skin Barrier Function NCT06943469NA25 sites📍 Bruges📍 Brussels📍 Namur Société des Produits Nestlé (SPN) · Tests: Test formula, Control formula CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis NCT07204561NA1 site📍 Roma Societa Italiana di Dermatologia Medica, Chirurgica, Esteti… · Tests: CeraVe Moisturizing Cream, Galenico A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis. NCT05689151n/a30 sites📍 Amiens📍 Besançon📍 Bezannes Pfizer · Tests: Abrocitinib A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD) NCT07544862n/a1 site📍 Beijing Chengdu Kangnuoxing Biopharma,Inc. · Tests: Stapokibart A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis NCT07693738Phase 11 site📍 Shanghai Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Tests: SSGJ-716, Placebo Global Healthcare Study on Atopic Dermatitis NCT07659756n/a1 site📍 Zurich Julia Tatjana Maul Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study NCT07297602Phase 21 site📍 Al Mansurah Nora Mohamed Abdelrazik · Tests: Oral roflumilast Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 NCT07453602Phase 17 sites📍 Miami📍 Miami📍 Plainfield Arcutis Biotherapeutics, Inc. · Tests: ARQ-234, Placebo Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT NCT05938478n/a1 site📍 La Jolla University of California, San Diego · Tests: Tralokinumab Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD) NCT07767253Phase 35 sites📍 Beijing📍 Beijing📍 Guangzhou Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Tests: 611, 611, Matching placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy